Biomind Labs Inc (FRA:3XI) Stock Price, Trades & News

Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.02
Equity-to-Asset	-130.9
Debt-to-Equity	-0.43
Debt-to-EBITDA	-0.96
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	35.8
	3-Year EPS without NRI Growth Rate	34.3
	3-Year FCF Growth Rate	70.5
	3-Year Book Growth Rate	-83.7

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	14-Day RSI	30.37
	6-1 Month Momentum %	-41.13
	12-1 Month Momentum %	-85.16

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.01
	Quick Ratio	0.01
	Cash Ratio	0.01

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.2
	Shareholder Yield %	2.65

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	ROA %	-3096.2
	ROIC %	-86.77
	3-Year ROIIC %	221.97
	ROC (Joel Greenblatt) %	-4028.57
	Moat Score	2

GF Value Rank

	Name	Current	Vs Industry		Vs History
	EV-to-EBIT	-5.44
	EV-to-EBITDA	-5.44
	EV-to-FCF	-33.01
	Earnings Yield (Greenblatt) %	-18.38
	FCF Yield %	-3.69

GF Value™

FRA:3XI

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 3XI. Try a 7-Day Free Trial to check it out.

Biomind Labs Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Biomind Labs Inc Stock Events

Financials Calendars

	Event	Date	Price (€)
No Event Data

Press Release

	Subject	Date
	Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States	2026-04-20
	Biomind Labs Announces CAD $2.52 Million Private Placement Financing	2026-01-27
	Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood	2025-12-03
	Biomind Labs Announces Revocation of Cease Trade Order	2025-11-25
	Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board	2025-11-18
	Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies	2024-11-20
	Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways	2024-07-18
	Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways	2024-07-18

10/Page

Articles on Biomind Labs Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.